Company Overview
Park Ha Biological Technology Co., Ltd. functions as an investment holding company focused on the development and marketing of skincare products within the People's Republic of China. The enterprise operates specifically within the Consumer Defensive sector and the Household & Personal Products industry, a classification that typically denotes businesses providing essential goods with relatively stable demand patterns. In terms of operational scale, the company maintains a market capitalization of $3.33M, generates annual revenue of $2.52M, and employs a workforce of 41 individuals. These specific financial metrics indicate that Park Ha Biological Technology Co., Ltd. is a micro-cap entity with very limited revenue generation relative to its market capitalization, suggesting a position as a small-scale player with significant volatility potential rather than a large-cap blue-chip stock. The disparity between the $3.33M market cap and the $2.52M revenue further highlights the market's assessment of the company's future earnings potential and risk profile, as the market values the firm at only slightly more than its annual sales output.
Financial Health
The company reported a revenue of $2.52M over the trailing twelve months, yet recorded a net income of $-24,364,752 and an EBITDA of $-24,039,532, revealing a severe structural disconnect where operating costs and expenses vastly exceed revenue generation. This massive negative gap between the $2.52M revenue and the $-24.3M net loss indicates a cost structure where non-operating expenses, interest, or other charges have overwhelmed core business operations, resulting in a total loss rather than a profitable operation. Free cash flow stands at $-14,219,369, which signifies that the company is consuming cash reserves at a rapid rate and lacks the financial flexibility to fund operations or capital expenditures without external financing. Margins reflect this distress, with a Gross Margin of 94.4% indicating high production efficiency or product pricing power, contrasted sharply by an Operating Margin of -344.8% and a Profit Margin of 0.0% that underscores the inability to cover overhead costs. Regarding liquidity and leverage, the company holds $3.79M in cash against total debt of $180,169, creating a net cash position, although the Debt to Equity ratio of 4.51 suggests high leverage relative to shareholders' equity. The Current Ratio of 2.92 indicates that the company possesses 2.92 dollars of current assets for every dollar of current liabilities, suggesting adequate short-term liquidity to meet obligations despite the overall loss-making status. Return on Equity is reported at -885.8% and Return on Assets at -334.1%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate returns.
Valuation Assessment
Valuation multiples for the company show significant limitations due to earnings losses, as the Trailing P/E Ratio is listed as N/A and the Forward P/E is also N/A, implying that traditional earnings-based valuation methods cannot be applied given the negative net income trajectory. The Price to Book ratio is 0.18, indicating that the market values the company at less than 20% of its book value, which suggests the market perceives significant risks or a lack of tangible asset backing relative to the share price. The Price to Sales ratio is 1.32, and the EV/EBITDA is 0.12; these alternative metrics suggest the company is trading at a discount to sales but offer limited insight into profitability given the negative EBITDA figure. Price action over the last year has been extreme, with a 52-Week High of $2074.50 and a 52-Week Low of $1.02, illustrating a massive range of volatility where the current trading environment could be positioned anywhere within this vast spread depending on market sentiment. The Beta is listed as N/A, meaning standard market volatility comparisons relative to the broader market index cannot be calculated due to insufficient price data frequency or stability.
Growth & Income
Revenue growth year-over-year has contracted by -15.9%, while earnings growth is listed as N/A due to the negative earnings base, indicating that the company is shrinking in revenue and unable to demonstrate earnings expansion. The company does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which means the firm reinvests its limited resources or relies on external capital rather than distributing income to shareholders. Given the negative net income of $-24,364,752, the company is technically unable to sustain a dividend payout from retained earnings, forcing it to operate as a non-dividend payer that seeks growth through other means despite the current revenue decline. Overall, the growth and income profile is characterized by negative revenue momentum and a complete absence of dividend income, presenting a scenario typical of distressed or early-stage biotech firms seeking turnaround opportunities rather than steady income generation.